Raymond James & Associates Genmab A/S Call Options Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GMAB
# of Institutions
232Shares Held
48.5MCall Options Held
6.8KPut Options Held
27.6K-
Alliancebernstein L.P. New York, NY15.2MShares$403 Million0.14% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$134 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA4.23MShares$112 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.77MShares$73.2 Million0.4% of portfolio
-
Wellington Management Group LLP Boston, MA2.31MShares$61 Million0.01% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $17.4B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...